



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




AZD 1390

Item No. 36498

CAS Registry No.: 2089288-03-7
Formal Name: 7-fluoro-1,3-dihydro-3-methyl-1-(1-methylethyl)-8-[6-[3-(1-piperidinyl)propoxy]-3-pyridinyl]-2H-imidazo[4,5-c]quinolin-2-one

MF: C₂₇H₃₂FN₅O₂
FW: 477.6
Purity: ≥98%
UV/Vis.: λ_{max}: 249, 269 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZD 1390 is supplied as a solid. A stock solution may be made by dissolving the AZD 1390 in the solvent of choice, which should be purged with an inert gas. AZD 1390 is soluble in DMSO.

Description

AZD 1390 is an inhibitor of Ataxia-telangiectasia mutated (ATM) kinase (IC₅₀ = 0.78 nM).¹ It is selective for ATM over Ataxia-telangiectasia and Rad3-related protein/kinase (ATR), PI3K, mammalian target of rapamycin (mTOR), and DNA protein kinase (DNA-PK; IC₅₀s = >30, >12, >16, and >29.9 μM, respectively). AZD 1390 (10 nM) sensitizes glioma cells expressing mutant, but not wild-type, p53 to ionizing radiation. Oral administration of AZD 1390 (20 mg/kg twice daily), in combination with radiation, reduces the growth of brain metastases and increases survival in an NCI H2228 lung carcinoma mouse xenograft model.

Reference

1. Durant, S.T., Zheng, L., Wang, Y., *et al.* The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. *Sci. Adv.* **4**(6), eaat1719 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/14/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM